---
title: "Guohai Securities: Maintains \"Buy\" rating on LMGF, with significant year-on-year improvement in performance for the first half of the year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248727889.md"
description: "Guohai Securities maintains a \"Buy\" rating on LMGF, expecting a significant year-on-year improvement in performance in the first half of 2025, mainly benefiting from rising product prices and increased sales volume. The company's leading products have a high market share and strong demand, with production operating at full capacity. The second half of the year will enter the sales peak season in the South American market, and the demand for fungicide products is expected to continue to rise. In addition, the company is accelerating the construction of its R&D platform to enhance product performance and production economics. Based on the improved prosperity of core products, the profit forecast has been adjusted"
datetime: "2025-07-16T06:43:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248727889.md)
  - [en](https://longbridge.com/en/news/248727889.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248727889.md)
---

# Guohai Securities: Maintains "Buy" rating on LMGF, with significant year-on-year improvement in performance for the first half of the year

Guohai Securities research report pointed out that benefiting from the rise in product prices, LMGF's performance in the first half of 2025 has significantly improved year-on-year. This is mainly due to the year-on-year increase in sales volume and prices of the company's main products, the improvement in gross profit margin, and the increase in investment income from the performance of affiliated companies. The domestic market share of the company's leading product, Mancozeb, is approximately 70%-80%; the domestic market share of Abamectin is approximately 25%-35%; and the domestic market share of Methomyl is approximately 20%-30%. Additionally, the demand for Abamectin, Methomyl, and Mancozeb is strong, and the company is currently operating at full capacity with sufficient sales orders on hand. The second half of the year will enter the sales peak season in the South American market, and it is expected that the market demand for fungicide products Mancozeb and Bacillus will support continued growth. Furthermore, the company is accelerating the construction of its R&D platform, with the synthetic biology laboratory officially completed and put into use in October 2024, effectively enhancing strain performance, biosynthesis efficiency, enzyme catalytic ability, product purity, and production economics. Based on the improved market conditions for the company's core products Mancozeb, Bacillus, Abamectin, and Methomyl, the company's profit forecast has been adjusted, maintaining a "Buy" rating

### Related Stocks

- [002734.CN](https://longbridge.com/en/quote/002734.CN.md)

## Related News & Research

- [FACTBOX-Here are the Democrats taking early steps in potential 2028 White House bids](https://longbridge.com/en/news/286890348.md)
- [Strathmore Confirms 85% Mineralization Hit Rate at Agate | SUUFF Stock News](https://longbridge.com/en/news/287092474.md)
- [Polytechnic students create AI chatbot to improve access to special needs resources and support](https://longbridge.com/en/news/286932477.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [12:45 ETInventHelp Inventor Develops New Bandage Dispenser (TLS-1305)](https://longbridge.com/en/news/286946419.md)